US clinics avoiding government oversight of ‘stem cell’ treatments – Medical Xpress
|
US clinics avoiding government oversight of ‘stem cell‘ treatments
Medical Xpress Clinics across the United States are advertising stem cell treatments that attempt to take advantage of what they perceive as exceptions in FDA regulations, according to bioethicist Leigh G. Turner, PhD, Associate Professor, University of Minnesota … |
Regulatory Focus |
German Regulators Decry Lack of Trial Transparency in Look at Stem Cell …
Regulatory Focus The German Institute for Quality and Efficiency in Health Care (IQWiG) has found recent clinical data on the use of stem cell transplantation to treat multiple myeloma—a rare and deadly form of cancer—to be inconclusive. |
|
OncoMed Publishes Data on Tarextumab’s Anti-Cancer Stem Cell Activity in …
CNNMoney Preclinical studies have suggested that tarextumab exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, tarextumab appears to have anti-cancer stem cell effects, and (2) tarextumab affects pericytes, impacting stromal and … |
|
OncoMed Publishes Data on Tarextumab’s Anti-Cancer Stem Cell Activity in …
CNNMoney Preclinical studies have suggested that tarextumab exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, tarextumab appears to have anti-cancer stem cell effects, and (2) tarextumab affects pericytes, impacting stromal and … |
|
OncoMed Publishes Data on Tarextumab’s Anti-Cancer Stem Cell Activity in …
MarketWatch Preclinical studies have suggested that tarextumab exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, tarextumab appears to have anti-cancer stem cell effects, and (2) tarextumab affects pericytes, impacting stromal and … |
|
OncoMed Publishes Data on Tarextumab’s Anti-Cancer Stem Cell Activity in …
MarketWatch Preclinical studies have suggested that tarextumab exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, tarextumab appears to have anti-cancer stem cell effects, and (2) tarextumab affects pericytes, impacting stromal and … |
Phys.Org |
A method to identify human induced pluripotent stem cells in the lab using a …
Phys.Org This week, the United States Patent and Trademark Office issued a major patent to two scientists from the UCLA Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research, William Lowry, Ph.D., and Kathrin Plath, Ph.D. The patent covers a … Eye Stem Cell Therapy Moves AheadThe Scientist AIM’s Tory Williams Unites Patient Advocacy With Stem Cell Funding In The …Seeking Alpha Public Release: 30-Apr-2015 First embryonic stem cell therapy safety trial in …EurekAlert (press release) Nature.com –UConn Today (blog) –Genetic Literacy Project all 27 news articles » |